Sociedad Americana de Hirudoterapia

Federal Office of Public Health — Bundesamt für Gesundheit (BAG)

FOPH / BAG · Switzerland · europe

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Swiss federal public-health authority — sets reimbursement scope under KLV including the historic 2017 decision to make hirudotherapy permanently reimbursable when delivered by FMH-credentialed physicians.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Switzerland
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Krankenversicherungsgesetz (KVG, SR 832.10)
  • Krankenpflege-Leistungsverordnung (KLV, SR 832.112.31), Anhang 1
  • Bundesverfassung Art. 118a — Komplementärmedizin

Prescriber Requirements

  • FMH-credentialed physician with Fähigkeitsausweis in complementary-medicine speciality is the prerequisite for OKP reimbursement
  • Naturheilpraktiker with federal diploma have legal scope but typically not OKP-reimbursed

Supply Chain & GMP

Out of scope — FOPH/BAG sets reimbursement, not product regulation (Swissmedic handles the device side).

Import/Export Rules

Out of scope — Swissmedic handles import authorisation for the device itself.

Reimbursement Context

Hirudotherapy delivered by an FMH-credentialed physician under Anhang 1 KLV is fully OKP-reimbursable as of 2017 — a unique Western status conferred by constitutional anchoring (Art. 118a BV).

ASH Editorial Notes

FOPH/BAG is a payer-side regulator paired with Swissmedic on the product-side. ASH presents them as separate entries because the reimbursement decision (2017) is editorially distinct from the device-clearance pathway.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.